세계 피부 및 전신 리슈마니어증 시장 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2031년)

Persistence Market Research has recently released a detailed report on the global cutaneous & systemic leishmaniasis market. This report provides an in-depth evaluation of critical market dynamics, including drivers, trends, opportunities, and challenges, offering a thorough understanding of the market structure.

Key Insights:

• Cutaneous & Systemic Leishmaniasis Market Value (2024F): US$ 366.04 million
• Projected Market Value (2031F): USD 448.5 Million
• Global Market Growth Rate (CAGR 2024 to 2031): 2.9%

Cutaneous & Systemic Leishmaniasis Market - Report Scope:

The cutaneous & systemic leishmaniasis market addresses the growing need for effective treatments against leishmaniasis, a disease primarily affecting tropical regions. This market plays a crucial role in providing therapeutic options to manage and cure the disease, thereby improving patient outcomes and reducing morbidity. The market caters to various segments, including combinational drug therapies and novel treatment alternatives, with growth driven by increasing disease prevalence and heightened awareness about prevention and treatment.

Market Growth Drivers:

The global cutaneous & systemic leishmaniasis market is driven by several key factors, including the rising prevalence of the disease in tropical regions, which necessitates the development of effective treatment options. The high clinical cure rate achieved through combinational drug therapy is another significant driver, as this approach has shown increased effectiveness in treating both cutaneous and systemic leishmaniasis. Additionally, substantial investments in research and development by market players to create novel treatment alternatives are expected to open new avenues for market growth. Favorable reimbursement policies offered by governments and private insurers further stimulate the market by making treatments more accessible to patients.

Market Restraints:

Despite its growth potential, the cutaneous & systemic leishmaniasis market faces several challenges. The high cost of treatment is a major barrier, as the drugs used for treating leishmaniasis are often expensive. Moreover, these drugs can cause serious adverse effects, which may limit their use and deter patients from seeking treatment. However, ongoing research into new treatment options is expected to mitigate these concerns by providing safer and more affordable therapies in the future.

Market Opportunities:

The cutaneous & systemic leishmaniasis market presents substantial growth opportunities driven by increased investments in research and development, leading to the discovery of novel therapies with higher efficacy and fewer side effects. The implementation of favorable reimbursement policies globally also offers significant potential for market expansion, as it increases patient access to necessary treatments. Additionally, the ongoing clinical trials for new drugs and therapies, with positive outcomes anticipated, are likely to create further opportunities for market players.

Key Questions Answered in the Report:

• What are the primary factors driving the growth of the cutaneous & systemic leishmaniasis market globally?
• Which types of therapies are leading the demand in the treatment of leishmaniasis?
• How are technological advancements influencing the competitive landscape of the cutaneous & systemic leishmaniasis market?
• Who are the key players in the cutaneous & systemic leishmaniasis market, and what strategies are they employing to enhance their market presence?
• What are the emerging trends and future prospects in the global cutaneous & systemic leishmaniasis market?

Competitive Intelligence and Business Strategy:

Leading players in the global cutaneous & systemic leishmaniasis market, including companies such as Gilead Sciences, Inc., Sanofi S.A., and GlaxoSmithKline plc, focus on innovation, product differentiation, and strategic partnerships to gain a competitive edge. These companies invest in research and development to enhance drug efficacy, reduce side effects, and improve patient compliance. Collaborations with healthcare providers, research institutions, and governments facilitate market access and adoption of new treatments. Emphasis on patient-centric solutions, affordability, and safety drives growth and strengthens market positioning in the dynamic cutaneous & systemic leishmaniasis industry.

Key Companies Profiled:

• GlaxoSmithKline plc.
• Gilead Sciences, Inc.
• Profounda Pharmaceuticals
• Knight Therapeutics Inc.
• Janssen Global Services, LLC
• Albert David Ltd
• Jubilant Life Sciences Ltd.
• Novartis AG
• Sanofi
• Endo Pharmaceuticals Inc
• Bristol-Myers Squibb Company
• United Biotech Pvt. Ltd.

Cutaneous & Systemic Leishmaniasis Market Categorization

Cutaneous & Systemic Leishmaniasis Market by By Drug Class

• Pentavalent Antimonials
• Antifungal Drugs
• Anti-Lesihmanial/Antimicrobial Drugs

Cutaneous & Systemic Leishmaniasis Market By Route of Administration

• Oral
• Injectable
• Topical

Cutaneous & Systemic Leishmaniasis Market By Indication

• Cutaneous Leishmaniasis
• Mucosal Leishmaniasis
• Visceral Leishmaniasis

Cutaneous & Systemic Leishmaniasis Market By Distribution Channel

• Hospital Pharmacies,
• Retail Pharmacies
• Drug Stores
• Online Pharmacies

Cutaneous & Systemic Leishmaniasis Market by Region

• North America
• Latin America
• Europe
• Asia Pacific
• Middle East & Africa (MEA)

Table of Contents

1. Executive Summary

• 1.1. Global Market Outlook
• 1.2. Market Analysis
• 1.3. PMR Analysis and Recommendations
• 1.4. Wheel of Fortune

2. Market Overview

• 2.1. Market Definition
• 2.2. Market Taxonomy

3. Key Market Trends

• 3.1. Key Trends Impacting the Market
• 3.2. Product Innovation Trends
• 3.3. New Launches / Patents/Market Background

4. Key Success Factors

• 4.1. Product Adoption / Awareness Analysis
• 4.2. Pipeline Assessment
• 4.3. Leishmaniasis Epidemiology

5. Global Market Demand / Consumption (value or size in US$ Mn) Analysis

• 5.1. Historical Market Value (US$ Mn) Analysis
• 5.2. Current and Future Market Value (US$ Mn) Projections
  • 5.2.1. Y-o-Y Growth Trend Analysis
  • 5.2.2. Absolute $ Opportunity Analysis

6. Market Context

• 6.1. Key Regulations
• 6.2. Macro-Economic Factors
• 6.3. Forecast Factors - Relevance & Impact
• 6.4. Market Dynamics
  • 6.4.1. Drivers
  • 6.4.2. Restraints
  • 6.4.3. Opportunity Analysis

7. Global Cutaneous and Systemic Leishmaniasis Analysis 2019-2023 and Forecast 2024-2031, By Drug Class

• 7.1. Introduction
  • 7.1.1. Market Value Share Analysis By Drug Class
  • 7.1.2. Y-o-Y Growth Analysis By Drug Class
• 7.2. Historical Market Size and Volume Analysis By Drug Class 2019-2023
• 7.3. Market Size and Volume Forecast By Drug Class 2024-2031
  • 7.3.1. Pentavalent Antimonials
  • 7.3.2. Antifungal Drugs
  • 7.3.3. Antimicrobial / Anti-leishmanial
• 7.4. Market Attractiveness Analysis By Drug Class

8. Global Cutaneous and Systemic Leishmaniasis Analysis 2019-2023 and Forecast 2024-2031, By Route of Administration

• 8.1. Introduction
  • 8.1.1. Market Value Share Analysis By Route of Administration
  • 8.1.2. Y-o-Y Growth Analysis By Route of Administration
• 8.2. Historical Market Size and Volume Analysis By Route of Administration 2019-2023
• 8.3. Market Size and Volume Forecast By Route of Administration 2024-2031
  • 8.3.1. Oral
  • 8.3.2. Injectable
  • 8.3.3. Topical
• 8.4. Market Attractiveness Analysis By Drug Class

9. Global Cutaneous and Systemic Leishmaniasis Analysis 2019-2023 and Forecast 2024-2031, By Indication Type

• 9.1. Introduction
  • 9.1.1. Market Value Share Analysis By Indication Type
  • 9.1.2. Y-o-Y Growth Analysis By Indication Type
• 9.2. Historical Market Size and Volume Analysis By Indication Type 2019-2023
• 9.3. Market Size and Volume Forecast By Indication Type 2024-2031
  • 9.3.1. Cutaneous Leishmaniasis
  • 9.3.2. Mucosal Leishmaniasis
  • 9.3.3. Visceral Leishmaniasis
• 9.4. Market Attractiveness Analysis By Indication Type

10. Global Cutaneous and Systemic Leishmaniasis Market Analysis 2019-2023 and Forecast 2024-2031, By Distribution Channel

• 10.1. Introduction
  • 10.1.1. Market Value Share Analysis By Distribution Channel
  • 10.1.2. Y-o-Y Growth Analysis By Distribution Channel
• 10.2. Historical Market Size and Volume Analysis By Distribution Channel, 2019-2023
• 10.3. Market Size and Volume Forecast By Distribution Channel 2024-2031
  • 10.3.1. Hospital Pharmacies
  • 10.3.2. Retail Pharmacies
  • 10.3.3. Drug Stores
  • 10.3.4. Online Pharmacies
• 10.4. Market Attractiveness Analysis By Distribution Channel

11. Global Cutaneous and Systemic Leishmaniasis Market Analysis 2019-2023 and Forecast 2024-2031, By Region

• 11.1. Introduction
  • 11.1.1. Market Value Share Analysis By Region
  • 11.1.2. Y-o-Y Growth Analysis By Region
• 11.2. Historical Market Size and Volume Analysis By Region 2019-2023
• 11.3. Market Size and Volume Forecast By Region 2024-2031
  • 11.3.1. North America
  • 11.3.2. Latin America
  • 11.3.3. Europe
  • 11.3.4. Asia Pacific Excl. Japan
  • 11.3.5. Japan
  • 11.3.6. Oceania
  • 11.3.7. Middle East and Africa Market Attractiveness Analysis By Region

12. North America Cutaneous and Systemic Leishmaniasis Market Analysis 2019-2023 and Forecast 2024-2031

• 12.1. Introduction
• 12.2. Historical Market Size and Volume Analysis By Market Segments, 2019-2023
• 12.3. Market Size and Volume Forecast By Market Segments, 2024-2031
  • 12.3.1. By Country
    • 12.3.1.1. U.S.
    • 12.3.1.2. Canada
  • 12.3.2. By Drug Class
  • 12.3.3. By Route of Administration
  • 12.3.4. By Indication Type
  • 12.3.5. By Distribution Channel
• 12.4. Market Attractiveness Analysis
• 12.5. Key Market Participants - Intensity Mapping
• 12.6. Drivers and Restraints - Impact Analysis

13. Latin America Cutaneous and Systemic Leishmaniasis Market Analysis 2019-2023 and Forecast 2024-2031

• 13.1. Asia Pacific Excl. Japan
• 13.2. Japan
• 13.3. Oceania
• 13.4. Middle East and Africa Market Attractiveness Analysis By Region

14. North America Cutaneous and Systemic Leishmaniasis Market Analysis 2019-2023 and Forecast 2024-2031

• 14.1. Introduction
• 14.2. Historical Market Size and Volume Analysis By Market Segments, 2019-2023
• 14.3. Market Size and Volume Forecast By Market Segments, 2024-2031
  • 14.3.1. By Country
    • 14.3.1.1. U.S.
    • 14.3.1.2. Canada
  • 14.3.2. By Drug Class
  • 14.3.3. By Route of Administration
  • 14.3.4. By Indication Type
  • 14.3.5. By Distribution Channel
• 14.4. Market Attractiveness Analysis
• 14.5. Key Market Participants - Intensity Mapping
• 14.6. Drivers and Restraints - Impact Analysis

15. Latin America Cutaneous and Systemic Leishmaniasis Market Analysis 2019-2023 and Forecast 2024-2031

• 15.1. Introduction
• 15.2. Historical Market Size and Volume Analysis By Market Segments, 2019-2023 Market Size
• 15.3. Market Size and Volume Forecast By Market Segments, 2024-2031
  • 15.3.1. By Country
    • 15.3.1.1. Brazil
    • 15.3.1.2. Mexico
    • 15.3.1.3. Rest of Latin America
  • 15.3.2. By Drug Class
  • 15.3.3. By Route of Administration
  • 15.3.4. By Indication Type
  • 15.3.5. By Distribution Channel
• 15.4. Market Attractiveness Analysis
• 15.5. Key Market Participants - Intensity Mapping
• 15.6. Drivers and Restraints - Impact Analysis

16. Europe America Cutaneous and Systemic Leishmaniasis Market Analysis 2019-2023 and Forecast 2024-2031

• 16.1. Introduction
• 16.2. Historical Market Size (US$ Mn) Trend Analysis By Country, 2019-2023
• 16.3. Market Size and Volume Forecast By Market Segments, 2024-2031
  • 16.3.1. By Country
    • 16.3.1.1. Germany
    • 16.3.1.2. Italy
    • 16.3.1.3. France
    • 16.3.1.4. U.K.
    • 16.3.1.5. Spain
    • 16.3.1.6. BENELUX
    • 16.3.1.7. Nordic
    • 16.3.1.8. Russia
    • 16.3.1.9. Rest of Europe
  • 16.3.2. By Drug Class
  • 16.3.3. By Route of Administration
  • 16.3.4. By Indication Type
  • 16.3.5. By Distribution Channel
• 16.4. Market Attractiveness Analysis
• 16.5. Key Market Participants - Intensity Mapping
• 16.6. Drivers and Restraints - Impact Analysis

17. Asia-Pacific Excluding Japan (APEJ) Cutaneous and Systemic Leishmaniasis Market Analysis 2019-2023 and Forecast 2024-2031

• 17.1. Introduction
• 17.2. Historical Market Size (US$ Mn) Trend Analysis By Country, 2019-2023
• 17.3. Market Size and Volume Forecast By Market Segments, 2024-2031
  • 17.3.1. By Country
    • 17.3.1.1. China
    • 17.3.1.2. India
    • 17.3.1.3. South Korea
    • 17.3.1.4. ASEAN
    • 17.3.1.5. Rest of APEJ
  • 17.3.2. By Drug Class
  • 17.3.3. By Route of Administration
  • 17.3.4. By Indication Type
  • 17.3.5. By Distribution Channel
• 17.4. Market Attractiveness Analysis
• 17.5. Key Market Participants - Intensity Mapping
• 17.6. Drivers and Restraints - Impact Analysis

18. Japan Cutaneous and Systemic Leishmaniasis Market Analysis 2019-2023 and Forecast 2024-2031

• 18.1. Introduction
• 18.2. Historical Market Size and Volume Analysis By Market Segments,
• 18.3. 2019-2023
• 18.4. Market Size and Volume Forecast By Market Segments, 2024-2031
  • 18.4.1. By Drug Class
  • 18.4.2. By Route of Administration
  • 18.4.3. By Indication Type
  • 18.4.4. By Distribution Channel
• 18.5. Market Attractiveness Analysis
• 18.6. Key Market Participants - Intensity Mapping
• 18.7. Drivers and Restraints - Impact Analysis

19. Oceania Cutaneous and Systemic Leishmaniasis Market Analysis 2019-2023 and Forecast 2024-2031

• 19.1. Introduction
• 19.2. Historical Market Size (US$ Mn) Trend Analysis By Country, 2019-2023
• 19.3. Market Size and Volume Forecast By Market Segments, 2024-2031
  • 19.3.1. By Country
    • 19.3.1.1. Australia
    • 19.3.1.2. New Zealand
  • 19.3.2. By Drug Class
  • 19.3.3. By Route of Administration
  • 19.3.4. By Indication Type
  • 19.3.5. By Distribution Channel
• 19.4. Market Attractiveness Analysis
• 19.5. Key Market Participants - Intensity Mapping
• 19.6. Drivers and Restraints - Impact Analysis

20. Middle East and Africa (MEA) Cutaneous and Systemic Leishmaniasis Market Analysis 2019-2023 and Forecast 2024-2031

• 20.1. Introduction
• 20.2. Historical Market Size (US$ Mn) Trend Analysis By Country, 2019-2023
• 20.3. Market Size and Volume Forecast By Market Segments, 2024-2031
  • 20.3.1. By Country
    • 20.3.1.1. Northern Africa
    • 20.3.1.2. GCC Countries
    • 20.3.1.3. Turkey
    • 20.3.1.4. South Africa
    • 20.3.1.5. Rest of MEA
  • 20.3.2. By Drug Class
  • 20.3.3. By Route of Administration
  • 20.3.4. By Indication Type
  • 20.3.5. By Distribution Channel

21. Market Attractiveness Analysis

• 21.1. Tier Structure Analysis
• 21.2. Market Presence Analysis
  • 21.2.1. By Region
  • 21.2.2. Product Portfolio

22. Competition Analysis

• 22.1. Competition Dashboard
• 22.2. Company Deep Dive
  • 22.2.1. GlaxoSmithKline plc.
    • 22.2.1.1. Overview
    • 22.2.1.2. Product and Application Portfolio
    • 22.2.1.3. Production Footprint
    • 22.2.1.4. Sales Footprint
    • 22.2.1.5. Analyst Commentary
  • 22.2.2. Gilead Sciences, Inc.
    • 22.2.2.1. Overview
    • 22.2.2.2. Product and Application Portfolio
    • 22.2.2.3. Production Footprint
    • 22.2.2.4. Sales Footprint
    • 22.2.2.5. Analyst Commentary
  • 22.2.3. Profounda Pharmaceuticals
    • 22.2.3.1. Overview
    • 22.2.3.2. Product and Application Portfolio
    • 22.2.3.3. Production Footprint
    • 22.2.3.4. Sales Footprint
    • 22.2.3.5. Analyst Commentary
  • 22.2.4. Knight Therapeutics Inc.
    • 22.2.4.1. Overview
    • 22.2.4.2. Product and Application Portfolio
    • 22.2.4.3. Production Footprint
    • 22.2.4.4. Sales Footprint
    • 22.2.4.5. Analyst Commentary
  • 22.2.5. Janssen Global Services, LLC
    • 22.2.5.1. Overview
    • 22.2.5.2. Product and Application Portfolio
    • 22.2.5.3. Production Footprint
    • 22.2.5.4. Sales Footprint
    • 22.2.5.5. Analyst Commentary
  • 22.2.6. Albert David Ltd
    • 22.2.6.1. Overview
    • 22.2.6.2. Product and Application Portfolio
    • 22.2.6.3. Production Footprint
    • 22.2.6.4. Sales Footprint
    • 22.2.6.5. Analyst Commentary
  • 22.2.7. Jubilant Life Sciences Ltd.
    • 22.2.7.1. Overview
    • 22.2.7.2. Product and Application Portfolio
    • 22.2.7.3. Production Footprint
    • 22.2.7.4. Sales Footprint
    • 22.2.7.5. Analyst Commentary
  • 22.2.8. Novartis AG
    • 22.2.8.1. Overview
    • 22.2.8.2. Product and Application Portfolio
    • 22.2.8.3. Production Footprint
    • 22.2.8.4. Sales Footprint
    • 22.2.8.5. Analyst Commentary
  • 22.2.9. Sanofi
    • 22.2.9.1. Overview
    • 22.2.9.2. Product and Application Portfolio
    • 22.2.9.3. Production Footprint
    • 22.2.9.4. Sales Footprint
    • 22.2.9.5. Analyst Commentary
  • 22.2.10. Endo Pharmaceuticals Inc
    • 22.2.10.1. Overview
    • 22.2.10.2. Product and Application Portfolio
    • 22.2.10.3. Production Footprint
    • 22.2.10.4. Sales Footprint
    • 22.2.10.5. Analyst Commentary
  • 22.2.11. Bristol-Myers Squibb Company
    • 22.2.11.1. Overview
    • 22.2.11.2. Product and Application Portfolio
    • 22.2.11.3. Production Footprint
    • 22.2.11.4. Sales Footprint
    • 22.2.11.5. Analyst Commentary
  • 22.2.12. United Biotech Pvt. Ltd.
    • 22.2.12.1. Overview
    • 22.2.12.2. Product and Application Portfolio
    • 22.2.12.3. Production Footprint
    • 22.2.12.4. Sales Footprint
    • 22.2.12.5. Analyst Commentary

23. Research Methodology